3.17
0.02 (0.80%)
| Penutupan Terdahulu | 3.14 |
| Jumlah Dagangan | 1,047,150 |
| Harga / Jualan (P/S) | 9.81 |
| Harga / Buku (P/B) | 1.53 |
| Julat 52 Minggu |
| Margin Keuntungan | -259.60% |
| Margin Operasi (TTM) | -402.93% |
| EPS Cair (TTM) | -1.48 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 138.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.99% |
| Nisbah Semasa (MRQ) | 5.70 |
| Aliran Tunai Operasi (OCF TTM) | -80.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.06 M |
| Pulangan Atas Aset (ROA TTM) | -20.30% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | C4 Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.38 |
|
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.79% |
| % Dimiliki oleh Institusi | 91.87% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ADAMS KENDRA | - | 3.39 | -2,775 | -9,407 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,775 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -9,407 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 3.39 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ADAMS KENDRA | Pegawai | 18 Sep 2026 | Dibuang (-) | 2,775 | 3.39 | 9,407 |
| ADAMS KENDRA | Pegawai | 18 Sep 2026 | Pelaksanaan pilihan | 6,250 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |